NICE refuses to expand use of Roche’s IPF drug Esbriet
Essentially, this means that patients will have to wait until their disease has worsened - and lung function has been lost - before getting routine NHS access to the drug. “This is an illogical decision, to deny effective treatment in a condition that is irreversibly progressive and ultimately fatal,” said Dr Toby Maher, consultant physician at the Royal Brompton Hospital.